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July 20, 2010:317–20carring and interstitial fibrosis in the subendocardial regions of the
nterior and apical left ventricle, without significant cellular
nfiltrate. The pathologic findings were thought to be consistent
ith chronic ischemia in the distribution of the terminal circula-
ion (left anterior descending artery territory). The authors of this
arlier paper concluded that this portion of the heart had a
ombined ischemic blood supply coupled with an excessive de-
and on the limited circulation. Perhaps a similar pathophysiology
ontributed to the chest pain symptoms reported in their 59-year-
ld female patient.
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eply
e thank Dr. Symanski for his interest in our article describing a
are coronary anomaly (1). We are grateful that he brings to our
ttention the post-mortem results of Pete Maravich’s heart (2). We
gree that this anomaly, unbeknownst to us, has been previously
escribed.
It was interesting to read the post-mortem examination that
escribed a dilated heart weighing 650 g and having a left
entricular wall thickness of 15 mm. Equally interesting were the
ndings of myocardial fibrosis consistent with chronic ischemia.
r. Symanski questions whether a similar pathophysiology may be
ontributing to our patient’s chest pain.
At follow-up, our patient’s atypical chest pain had completely
esolved. On further review, our patient also had normal left
entricular volumes, mass, and ejection fraction. Cocker et al.
3) recently described the finding of myocardial fibrosis in elite
thletes using magnetic resonance imaging. We wonder
hether Pete Maravich’s history as an elite athlete in combi-
ation with this rare coronary anomaly partially explains his
ost-mortem findings.
Benjamin J. W. Chow, MD
aul J. Galiwango, MD
ngeline Law, MD
isha D’Mello, MD
University of Ottawa Heart Institute
ivision of Cardiology
0 Ruskin Street
oom 1220A
ttawa, Ontario K1Y 4W7
anada
-mail: bchow@ottawaheart.cadoi:10.1016/j.jacc.2009.10.091 eEFERENCES
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myocardial fibrosis with reduced cardiac function in elite high endur-
ance athletes: a cardiovascular magnetic resonance (CMR) study.
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ertebral Artery Stenting
ot Quite Ready for Prime Time!
therosclerotic vertebral artery (VA) stenosis is a significant cause
f vertebrobasilar ischemia. However, vertebral artery stenting
VAS) has not received the detailed scientific study that has been
ccorded to carotid artery stenting (CAS).
In their series, Jenkins et al. (1) show excellent results. These
esults add to the growing body of nonrandomized studies that
emonstrate the feasibility and relative safety of VAS (2). Based on
heir outcomes, the authors recommend a more liberal use of VAS.
owever, several issues remain unresolved that beg for a more
autious approach.
No recent study of sufficient size has investigated the impact of
ptimal medical regimen on the natural history of VA disease or
ompared it with VAS (3). Further, there are several unresolved
ssues regarding optimal endovascular strategy. Bilateral VA ste-
osis presents a clinical challenge. Unlike anterior circulation
schemia, vertebrobasilar ischemia symptoms are difficult to later-
lize to one side. It is not known whether unilateral VAS will
esolve the symptoms or whether bilateral VAS is indicated. The
uthors report that 54.3% patients had bilateral VA disease,
lthough only 6.3% of the subjects received bilateral stents. It is
nclear how the stented side was chosen and whether symptoms
esolved completely.
Subclavian artery stenosis without coexistent VA stenosis can
ause vertebrobasilar ischemia (4). In the current study, 29.2% of
he subjects had concurrent subclavian artery disease. It will be
seful to know whether the subclavian artery was also stented
oncomitantly.
The present study did not use distal embolic protection,
lthough this is the standard in CAS. This is an important issue in
AS with only limited data available (5).
Another important issue is restenosis. Unlike CAS, which has a
ow risk of restenosis, VAS has a significantly higher restenosis rate
6,7). Little information is available regarding the use of drug-
luting stents, although initial reports indicate a lower restenosis
ate (8).
Jenkins et al. (1) demonstrate that VAS is relatively safe and
easible. However, before more widespread use, VAS should
ndergo the same meticulous investigation as CAS has been
ccorded. This will involve a direct comparison with optimal
edical therapy and use of current endovascular standards (distal
mbolic protection and perhaps drug-eluting stents).
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eply
e thank Dr. Gupta for his comments on our paper (1) describing
ur experience treating symptomatic patients in whom medical
herapy had failed with vertebral artery stenting.
We are in complete agreement that this field will benefit from
ore data and larger clinical trials. Despite the fact that both
ertebral arteries supply a single basilar artery, conventional wis-
om has been that a single vertebral artery is adequate for posterior
irculation perfusion. Clearly there are infrequent clinical excep-
ions to this rule. Clinical practice has been to preserve the
ominant vertebral artery whenever possible.
In our series of patients, coexistent subclavian artery disease was
emonstrated in 29.2% of patients, one-half of whom were treated
oncurrently with a vertebral stent and the other half of whom
ere hemodynamically insignificant.There are several reasons for a lack of clinical trial data. One is the
nwillingness of providers to pay for vertebral artery stenting or to
eimburse for care performed as part of an investigational trial that has
enefited carotid stenting significantly. The second issue is that the
ertebral arteries are well treated with off-label balloons and stents,
hich diminish the enthusiasm of medical device manufacturers to
upport additional investigations.
As mentioned by Dr. Gupta, posterior circulation symptoms are
ore difficult to localize than anterior circulation symptoms.
atients with medically refractory vertebral basilar symptoms carry
5-year stroke rate of 30%, and if the disease is intracranial in
ocation, a 1-year stroke rate of 50% far exceeds the risk of anterior
irculation disease (2). Posterior circulation strokes account for a
inority of ischemic strokes (20% to 25%) (3), making it more
ifficult to enroll a sufficient number of patients in a clinical trial.
The effect of drug-eluting stents on vertebral artery restenosis
nd the utility of emboli protection devices have not been studied
n the vertebral circulation. Going forward, these are important
uestions that will need to be answered. Until then, we must do
ur best to treat patients using the best available data.
The encouraging results of our current series of vertebral
tenting, along with those of other single-center series (4,5),
trongly support a strategy of percutaneous catheter–based therapy
or medically refractory symptomatic patients with posterior cir-
ulation ischemia related to vertebral artery disease.
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